B9781416049197X50014 B9781416049197502097 Main
B9781416049197X50014 B9781416049197502097 Main
B9781416049197X50014 B9781416049197502097 Main
207
Ascites, anasarca
Hypertension
Pleural effusion
Xanthelasma (Fig. 2073)
Nails with Muehrckes lines (Fig. 2074)
Typically, patients present with severe peripheral edema,
exertional dyspnea, and abdominal fullness secondary to
ascites. There is a signicant amount of weight gain in most
patients.
CAUSE
Fig 2071
Fig 2073
Fig 2072
Fig 2074
707
207
Section 8: Kidneys
DIFFERENTIAL DIAGNOSIS
LABORATORY TESTS
IMAGING STUDIES
Ultrasound of kidneys
Chest x-ray
TREATMENT
Bed rest as tolerated, avoidance of nephrotoxic drugs, lowfat diet, uid restriction in hyponatremic patients; normal
protein intake unless urinary protein loss exceeds 10 g/24 hr
(some patients may require additional dietary protein to
prevent negative nitrogen balance and signicant protein
malnutrition).
Improved urinary protein excretion and serum lipid changes
have been observed with a low-fat soy protein diet providing 0.7 g of protein/kg/day. However, because of increased
risk of malnutrition, many nephrologists recommend normal protein intake.
Strict sodium restriction to help manage peripheral edema
Close monitoring of patients for development of peripheral
venous thrombosis and renal vein thrombosis because of
hypercoagulable state secondary to loss of antithrombin III
and other proteins involved in the clotting mechanism
Furosemide is useful for severe edema.
Use of ACE inhibitors to reduce proteinuria is generally indicated, even in normotensive patients.
Anticoagulant therapy should be administered as long
as patients have nephrotic proteinuria, an albumin level
20 g/L, or both.
The mainstay of therapy is treatment of the underlying disorder:
Minimal change disease generally responds to prednisone. Relapses can occur when corticosteroids are discontinued. In these individuals, cyclophosphamide and chlorambucil may be useful.
Focal and segmental glomerulosclerosis: corticosteroid
therapy is also recommended. However, response rate is approximately 35% to 40%, and most patients progress to
end-stage renal disease within 3 years.
Membranous glomerulonephritis: prednisone, may be
useful in inducing remission. Cytotoxic agents can be added
if there is poor response to prednisone.
Membranoproliferative glomerulonephritis: most patients are treated with steroid therapy and antiplatelet drugs.
Despite treatment, the majority of patients will progress to
end-stage renal disease within 5 years.
Fig 2075
Fat in the urine. A hyaline cast containing oval fat bodies, which are
tubular epithelial cells full of fat. Oval fat bodies often appear brown
in color.
(From Johnson RJ, Feehally J: Comprehensive Clinical Nephrology,
3rd ed. St. Louis, Mosby, 2007.)
708